Dominique Branger-Figarella

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 275 publications

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.

cIMPACT-NOW Update 12: Refining pathology-based risk stratification and grading for IDH-mutant gliomas.

Journal: Neuro-oncology

Published: February 25, 2026

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

Journal: Journal of neuro-oncology

Published: August 26, 2025

3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas.

3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas.

Journal: The Journal of clinical endocrinology and metabolism

Published: July 02, 2025

cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.

cIMPACT-NOW update 11: Proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors.

Journal: Brain pathology (Zurich, Switzerland)

Published: May 23, 2025

Long-Term Quality of Life and Functional Outcome Analysis of Surgically Managed Central Neurocytoma Patients: Results of a Multicenter Study.

Long-Term Quality of Life and Functional Outcome Analysis of Surgically Managed Central Neurocytoma Patients: Results of a Multicenter Study.

Journal: Neurosurgery

Published: May 22, 2025

Reply to "The time has come for an integrated and multiscale grading system for oligodendrogliomas IDH-mutant and 1p/19q co-deleted mixing imaging and histomolecular parameters".

Reply to "The time has come for an integrated and multiscale grading system for oligodendrogliomas IDH-mutant and 1p/19q co-deleted mixing imaging and histomolecular parameters".

Journal: Neuro-oncology

Published: April 18, 2025

Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.

Characteristics, outcome, and prognostic factors of young patients with central nervous system World Health Organization grade 3 oligodendrogliomas IDH-mutant and 1p/19q codeleted: A French POLA network study.

Journal: Cancer

Published: November 30, 2024

Comparative Clinical and Imaging-Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification.

Comparative Clinical and Imaging-Based Evaluation of Therapeutic Modalities in CNS Embryonal Tumours With PLAGL Amplification.

Journal: Neuropathology and applied neurobiology

Published: November 20, 2024

The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cells.

The GD3 ganglioside promotes cell growth, plasticity and chemotherapy resistance of human glioblastoma cancer stem cells.

Journal: Cancer cell international

Published: October 11, 2024

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2024

Brain tumoroids: Treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models.

Brain tumoroids: Treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models.

Journal: Neuro-oncology

Published: September 10, 2024

Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment.

Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment.

Journal: Journal of experimental & clinical cancer research : CR

Published: July 31, 2024

Showing 1-12 of 275

Last Updated: 09/26/2026